Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stake Boosted by Graham Capital Management L.P.

Graham Capital Management L.P. increased its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 148.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 76,232 shares of the company’s stock after purchasing an additional 45,542 shares during the quarter. Graham Capital Management L.P.’s holdings in Teva Pharmaceutical Industries were worth $1,680,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in TEVA. FMR LLC lifted its stake in Teva Pharmaceutical Industries by 30.7% in the fourth quarter. FMR LLC now owns 81,983,231 shares of the company’s stock valued at $1,806,910,000 after buying an additional 19,242,468 shares during the last quarter. Duquesne Family Office LLC lifted its stake in Teva Pharmaceutical Industries by 530.1% in the fourth quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company’s stock valued at $198,303,000 after buying an additional 7,569,450 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd lifted its stake in Teva Pharmaceutical Industries by 12.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company’s stock valued at $859,935,000 after buying an additional 4,418,961 shares during the last quarter. Todd Asset Management LLC bought a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at $58,243,000. Finally, Marshall Wace LLP lifted its stake in Teva Pharmaceutical Industries by 87.8% in the fourth quarter. Marshall Wace LLP now owns 5,155,402 shares of the company’s stock valued at $113,625,000 after buying an additional 2,410,420 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Price Performance

Shares of Teva Pharmaceutical Industries stock opened at $16.94 on Monday. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The company’s 50-day moving average price is $15.18 and its two-hundred day moving average price is $17.44. Teva Pharmaceutical Industries Limited has a 52 week low of $12.47 and a 52 week high of $22.80. The stock has a market cap of $19.21 billion, a PE ratio of -11.68, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The firm had revenue of $3.89 billion for the quarter, compared to analysts’ expectations of $3.99 billion. During the same period in the previous year, the business earned $0.48 earnings per share. Teva Pharmaceutical Industries’s revenue for the quarter was up 1.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. StockNews.com upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Wednesday, April 23rd. Hsbc Global Res raised Teva Pharmaceutical Industries to a “strong-buy” rating in a report on Monday, April 28th. UBS Group lowered their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Bank of America raised their price target on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a “buy” rating in a report on Thursday. Finally, Barclays lowered their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $23.71.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.